These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 18600540)

  • 1. Imatinib-resistant CML cells have low ENT activity but maintain sensitivity to gemcitabine.
    Leisewitz AV; Zimmerman EI; Jones SZ; Yang J; Graves LM
    Nucleosides Nucleotides Nucleic Acids; 2008 Jun; 27(6):779-86. PubMed ID: 18600540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts.
    Bertino P; Piccardi F; Porta C; Favoni R; Cilli M; Mutti L; Gaudino G
    Clin Cancer Res; 2008 Jan; 14(2):541-8. PubMed ID: 18223230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia.
    San José-Eneriz E; Agirre X; Jiménez-Velasco A; Cordeu L; Martín V; Arqueros V; Gárate L; Fresquet V; Cervantes F; Martínez-Climent JA; Heiniger A; Torres A; Prósper F; Roman-Gomez J
    Eur J Cancer; 2009 Jul; 45(10):1877-89. PubMed ID: 19403302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines.
    La Rosée P; Johnson K; Corbin AS; Stoffregen EP; Moseson EM; Willis S; Mauro MM; Melo JV; Deininger MW; Druker BJ
    Blood; 2004 Jan; 103(1):208-15. PubMed ID: 12933582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells.
    Carter BZ; Mak DH; Schober WD; Cabreira-Hansen M; Beran M; McQueen T; Chen W; Andreeff M
    Blood; 2006 Feb; 107(4):1555-63. PubMed ID: 16254145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of drug combinations containing imatinib for treatment of BCR-ABL+ leukemias.
    Kang Y; Hodges A; Ong E; Roberts W; Piermarocchi C; Paternostro G
    PLoS One; 2014; 9(7):e102221. PubMed ID: 25029499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation and targeting of Eg5, a mitotic motor protein in blast crisis CML: overcoming imatinib resistance.
    Carter BZ; Mak DH; Shi Y; Schober WD; Wang RY; Konopleva M; Koller E; Dean NM; Andreeff M
    Cell Cycle; 2006 Oct; 5(19):2223-9. PubMed ID: 16969080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of the dual Src/Abl kinase inhibitor AZD0530 on Philadelphia positive leukaemia cell lines.
    Gwanmesia PM; Romanski A; Schwarz K; Bacic B; Ruthardt M; Ottmann OG
    BMC Cancer; 2009 Feb; 9():53. PubMed ID: 19216789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells.
    Scappini B; Onida F; Kantarjian HM; Dong L; Verstovsek S; Keating MJ; Beran M
    Cancer; 2002 May; 94(10):2653-62. PubMed ID: 12173333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MiR-30e induces apoptosis and sensitizes K562 cells to imatinib treatment via regulation of the BCR-ABL protein.
    Hershkovitz-Rokah O; Modai S; Pasmanik-Chor M; Toren A; Shomron N; Raanani P; Shpilberg O; Granot G
    Cancer Lett; 2015 Jan; 356(2 Pt B):597-605. PubMed ID: 25305453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myelogenous leukemia cells.
    Peng XX; Tiwari AK; Wu HC; Chen ZS
    Chin J Cancer; 2012 Feb; 31(2):110-8. PubMed ID: 22098951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-kappaB signaling and depleting Bcr-Abl.
    Lu Z; Jin Y; Chen C; Li J; Cao Q; Pan J
    Mol Cancer; 2010 May; 9():112. PubMed ID: 20482842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dihydroartemisinin inhibits the Bcr/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib.
    Lee J; Shen P; Zhang G; Wu X; Zhang X
    Biomed Pharmacother; 2013 Mar; 67(2):157-63. PubMed ID: 23201011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targets and effectors of the cellular response to aurora kinase inhibitor MK-0457 (VX-680) in imatinib sensitive and resistant chronic myelogenous leukemia.
    Donato NJ; Fang D; Sun H; Giannola D; Peterson LF; Talpaz M
    Biochem Pharmacol; 2010 Mar; 79(5):688-97. PubMed ID: 19874801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation.
    Shi X; Chen X; Li X; Lan X; Zhao C; Liu S; Huang H; Liu N; Liao S; Song W; Zhou P; Wang S; Xu L; Wang X; Dou QP; Liu J
    Clin Cancer Res; 2014 Jan; 20(1):151-63. PubMed ID: 24334603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aberrant signalling by protein kinase CK2 in imatinib-resistant chronic myeloid leukaemia cells: biochemical evidence and therapeutic perspectives.
    Borgo C; Cesaro L; Salizzato V; Ruzzene M; Massimino ML; Pinna LA; Donella-Deana A
    Mol Oncol; 2013 Dec; 7(6):1103-15. PubMed ID: 24012109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance to imatinib of bcr/abl p190 lymphoblastic leukemia cells.
    Mishra S; Zhang B; Cunnick JM; Heisterkamp N; Groffen J
    Cancer Res; 2006 May; 66(10):5387-93. PubMed ID: 16707466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia.
    Golemovic M; Verstovsek S; Giles F; Cortes J; Manshouri T; Manley PW; Mestan J; Dugan M; Alland L; Griffin JD; Arlinghaus RB; Sun T; Kantarjian H; Beran M
    Clin Cancer Res; 2005 Jul; 11(13):4941-7. PubMed ID: 16000593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.
    Wolff NC; Veach DR; Tong WP; Bornmann WG; Clarkson B; Ilaria RL
    Blood; 2005 May; 105(10):3995-4003. PubMed ID: 15657179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined treatment of 3-hydroxyflavone and imatinib mesylate increases apoptotic cell death of imatinib mesylate-resistant leukemia cells.
    Kim JH; Song M; Kang GH; Lee ER; Choi HY; Lee C; Kim JH; Kim Y; Koo BN; Cho SG
    Leuk Res; 2012 Sep; 36(9):1157-64. PubMed ID: 22770910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.